目的

探析新辅助化疗分别联合保乳术和改良根治术治疗Ⅱ、Ⅲ期乳腺癌的应用效果。

方法

回顾性分析2017年1月至2019年12月收治的99例乳腺癌患者的临床资料，根据治疗方式不同分为对照组（新辅助化疗联合改良根治术，n=49例）和观察组（新辅助化疗联合保乳术，n=50例）。采用SPSS 25.0软件处理数据，围手术期指标、血清肿瘤标志物等计量资料以（x±s）表示，采用独立样本t检验；术后并发症发生率、复发生存情况等计数资料行χ²检验。P＜0.05为差异有统计学意义。

结果

两组患者手术时间比较，差异无统计学意义（P＞0.05）。观察组患者住院时间、拔除引流管时间短于对照组，且术中出血量低于对照组（P＜0.05）。两组患者术后的血清糖类抗原（CA）125、癌胚抗原（CEA）水平均较术前下降，但组间比较差异无统计学意义（P＞0.05）。观察组患者术后并发症总发生率（4.0%）低于对照组（18.4%），差异有统计学意义（P＜0.05）。观察组患者术后3年内复发率和生存率与对照组比较，差异无统计学意义（P＞0.05）。

结论

相比于改良根治术治疗，保乳术治疗乳腺癌患者也具有相似的治疗效果，但后者术中出血量更少，住院以及拔除引流管时间更短，术后并发症发生率更低。

Objective

To explore the effect of neoadjuvant chemotherapy combined with breast conserving surgery and modified radical surgery in the treatment of stage Ⅱ and Ⅲ breast cancer respectively.

Methods

Clinical data of 99 patients with breast cancer admitted from January 2017 to December 2019 were retrospectively analyzed, and divided into control group (neoadjuvant chemotherapy combined with modified radical surgery, n=49 cases) and observation group (neoadjuvant chemotherapy combined with breastconserving surgery, n=50 cases) according to different treatment methods.SPSS 25.0 software was used to process the data.Perioperative indicators, serum tumor markers and other measurement data were expressed as(x±s), and independent sample t test was used.The incidence of postoperative complications and recurrence survival were analyzed by Chi-square test.P＜0.05 was considered statistically significant.

Results

There was no significant difference in operation time between the two groups (P＞0.05).The duration of hospitalization and drainage tube removal in observation group was shorter than that in control group, and the amount of intraoperative blood loss was lower than that in control group (P＜0.05).The levels of carbohydrate antigen (CA)125 and carcinoembryonic antigen (CEA) in 2 groups were decreased after surgery, but there was no statistical significance between groups (P＞0.05).The total incidence of postoperative complications in observation group (4.0%) was lower than that in control group (18.4%), and the difference was statistically significant(P＜0.05).There was no significant difference in recurrence rate and survival rate between observation group and control group within 3 years after operation (P＞0.05).

Conclusion

Compared with modified radical surgery, breast-conserving surgery has a similar therapeutic effect for breast cancer patients, but the latter has less intraoperative blood loss, shorter hospitalization and drainage tube removal time, and a lower incidence of postoperative complications.